{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"36.8","value":"21.4"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"20.9","value":"7.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"PD-L1 expression >= 5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"24.7","value":"14.7"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"21.6","value":"11.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"PD-L1 expression < 5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.3","upperLimit":"64.3","value":"38.9"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"17.8","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"PD-L1 not quantifiable at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CIs were computed using the Clopper and Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to the date of objectively documented progression, up to approximately 103 months","title":"Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}